Results 21 to 30 of about 1,042 (177)

Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment [PDF]

Acta Dermato-Venereologica
Yoshihito Mima, Masako Yamamoto, Ken Iozumi   +2 more
doaj   +2 more sources

The Absence of Recent Systemic Therapy can be a Significant Risk Factor for Nemolizumab-associated Cutaneous Adverse Events in Patients with Prurigo Nodularis: A Single-centre Retrospective Study [PDF]

Acta Dermato-Venereologica
Yoshihito Mima, Masako Yamamoto, Ken Iozumi   +2 more
doaj   +2 more sources

Nemolizumab for treatment of lichen amyloidosis. [PDF]

JAAD Case Rep
Nakagawa S, Ueda-Hayakawa I, Fujimoto M.
europepmc   +2 more sources

A case of concurrent exacerbation of manifestations and asthma after the initiation of nemolizumab treatment for atopic dermatitis [PDF]

JAAD Case Reports
Michie Katsuta, MD, Ayaka Osawa, MD, Yozo Ishiuji, MD, Satomi Fujii, MD, Masahiro Kanbe, Akihiko Asahina, MD, Yoshimasa Nobeyama, MD   +6 more
doaj   +2 more sources

A case of acute generalized exanthematous pustulosis following administration of nemolizumab [PDF]

JAAD Case Reports
Alyssa Khoo, BA, Elgida Volpicelli, MD, Elle de Moll, MD   +2 more
doaj   +2 more sources

Nemolizumab for the treatment of refractory primary localized cutaneous amyloidosis in a nonatopic patient [PDF]

JAAD Case Reports
Gabriela Soto-Canetti, MPH, Jiwon Park, BA, Avi Bitterman, MD, Jordan Talia, MD   +3 more
doaj   +2 more sources

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies [PDF]

, 2022
[Background] Interleukin (IL)-31 affects the inflammatory response, is involved in epidermal barrier disruption in atopic dermatitis (AD) and plays a key role in pruritus.
Kabashima, K., Kawashima, M., Komazaki, H., Matsumura, T.   +3 more
core   +1 more source

Updated Review on Treatment of Atopic Dermatitis [PDF]

, 2023
La dermatitis atópica (DA) es una dermatosis inflamatoria crónica o crónicamente recurrente, asociada a múltiples desencadenantes y con un mecanismo fisiopatológico complejo. Se caracteriza por una expresión clínica, signos y síntomas heterogéneos.
Armario Hita, José Carlos, Carrascosa, J. M., Dodero-Anillo, J. M., Galán-Gutiérrez, M., Ruiz-Villaverde, R.   +4 more
core   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source

Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial

Journal of Dermatological Treatment, 2023
Background Data from the Japanese phase 3 Nemolizumab-JP01 study (JapicCTI-173740) found that nemolizumab in combination with topical treatments reduced pruritus associated with atopic dermatitis inadequately controlled with current therapies.
Kenji Kabashima, Takayo Matsumura, Yoshiteru Hayakawa, Makoto Kawashima, for the Nemolizumab-JP01 Study Group   +4 more
doaj   +1 more source